Table 1

Characteristics of included studies

SourceNo of subjectsDisease characteristicsActive treatmentsControl groupStudy duration (months)
Double-blind, placebo-controlled
Gorman et al, 20021940Active inflammatory ASEtanercept 25 mg BIWPlacebo3
Davis et al, 20037277Active inflammatory ASEtanercept 25 mg BIWPlacebo6
Calin et al, 20041084Active inflammatory ASEtanercept 25 mg BIWPlacebo3
van der Heijde et al, 200617356Active inflammatory ASEtanercept 25 mg BIW, etanercept 50 mg QWPlacebo3
Double-blind, active comparator
Braun et al, 2008 (ASCEND trial)8566Active inflammatory ASEtanercept 50 mg QWSulfasalazine ⩽3 g/day*4
Open-label
Gorman et al, 20021939Active inflammatory ASEtanercept 25 mg BIWN/A6
Davis et al, 2008†18267Active inflammatory ASEtanercept 25 mg BIWN/A42
Dijkmans et al, 2009‡16; Martin Mola et al, 2008‡2081Active inflammatory ASEtanercept 25 mg BIWN/A60
  • AS, ankylosing spondylitis; BIW, biweekly; QW, weekly.

  • *Subjects were titrated up to a maximum of 3 g of sulfasalazine per day and were required to tolerate at least 1.5 g of sulfasalazine daily. Mean daily dose = 2.8 g; †extension of study published as Davis et al, 2003; ‡first and second extensions of study reported by Calin et al, 2004.